New antibiotic to fight drug-resistant hospital superbug – The Siasat Daily



[ad_1]

Posted by Shameen on Jan 19, 2019, 18:19 IST Health

Sydney: The researchers have developed a new antibiotic that is a breakthrough in the fight against the deadly superbug of hospitals.

The Ramizol antibiotic has been shown to be safe and effective in combating Clostridium difficile (C. difficile) infection, which becomes resistant to traditional antibiotics caused by drug-resistant bacteria.

C. difficile is considered one of the most common infections contracted during hospital visits and the most likely cause of diarrhea in patients and hospital staff.

It causes a fatal infection in the large intestine and is more common in people who need to take antibiotics for a long time.

"Cases of C. difficile disease multiply and strains become more deadly. If there is an imbalance in your intestines, they may begin to develop and release toxins that attack the lining of the intestine, which causes symptoms, "said Ramiz Boulos, a research badociate at the University of California. Flinders University in Australia.

For the study, the team administered a high dose of a new clbad of antibiotics for 48 days to 48 rats to badess its safety.

The results, published in Scientific Reports, showed that when doses of the new antibiotic were administered to rats infected with the bacterium, a significant proportion of them survived the infection.

"Our research indicates that Ramizol is an extremely well tolerated antibiotic in rats, with good microbiology and good antioxidant properties. It also has high chemical stability and is scalable due to low manufacturing cost, which could make it a viable treatment option, "said Mr. Boulos.

In addition, a very high dose in the rat showed no mortality or side effects.
There was also no change in average body weight, weight gain, food consumption or food efficiency attributable to Ramizol in male and female rats.

"We believe that Ramizol could be the gold standard for the treatment of C. difficile infection and could become a star drug," said Boulos.

Source: IANS

[ad_2]
Source link